FREE Daily Stock Alerts From Stock-PR.com
Power3 Medical Products, Inc. (OTC:PWRM)
PWRM recently delivered four poster presentations at the 2010 ICAD. These presentations discussed PWRM’s diagnostic test, NuroPro, and focused on PWRM’s Alzheimer’s disease blood serum biomarkers, test and clinical validation trials.
“In preparation for commercialization, our objective at this meeting was to show how Power3 ’s protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer’s disease,” stated Dr. Ira L. Goldknopf, PWRM ’s President & Chief Scientific Officer. “It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3’s protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs.”
“We are pleased that our blood tests specifically diagnose Alzheimer’s in patients, both pre- and post-treatment,” commented Helen R. Park, MS, CEO of PWRM, “and that our scientific collaborators, Dr. Marwan Sabbagh, Medical and Scientific Director of the Banner Sun Health Medical Research Institute, and Dr. Lourdes R. Bosquez, President of the Woodlands Behavioral Institute, Inc., presented along with us at the meeting in Hawaii.”
“We are within striking distance of realizing an Alzheimer’s clinical diagnostic tool which I hope will lead to a greater understanding of the disease and buoy the pace of future therapeutic interventions,” added Marwan Sabbagh MD, Medical and Scientific Director of Banner Sun Health Medical Research Institute.
PWRM has filed several patent applications that are currently pending for its NuroPro technology. PWRM also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, PWRM has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China. PWRM has also published 6 articles on NuroPro in peer-reviewed scientific journals. PWRM intends to publish these latest findings as well.
Power3 Medical Products, Inc. strives to become the premier biotechnology company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technologies, world class quality procedures and superior research methodologies. PWRM will be guided in all of its dealings with its customers, partners, shareholders, associates and investors by the philosophy of best practices.
Douglas Lake Minerals Inc. (OTCBB:DLKM) is pleased to provide an update regarding its recently acquired Handeni Project which is located in the rapidly developing region of eastern Tanzania. Douglas Lakes’ 100% owned Handeni Project consists of four prospecting licenses covering approximately 800 km(2) which are directly adjacent to, and partly surround, Canaco Resources Inc’s (V.CAN) 200 km(2) Kilindi license which holds the Magambazi gold mineralization occurrence.
Douglas Lake Successfully Delineates Structural Controls on Gold Mineralization in the Four Handeni Project PLs
The Company is pleased to provide the results of the recent exploration program conducted on PLR PLR4973/2008, subsequently subdivided into four PL’s (PL6742/2010, PL6743/2010, PL6744/2010 and PL6779/2010), based on the outcomes of the first phase of the continuous exploration program conducted since 2008. This exploration phase included a fixed-wing aircraft flown aeromagnetic and radiometric survey at a line spacing of 200m and a height of 80m, subsequent interpretation of data and ground follow-up. The survey and interpretation was conducted according to internationally accepted standards by the Council for Geoscience, South Africa.
Interpretation of aeromagnetic data was successful in delineating prominent structural features including NW-SE shear zones of which five in the Company’s property area, with a total length of 143km, are given first order priority. These shear zones and their distances within the Company’s properties are: 1 - Southwestern shear zone (31km); 2 - Kimamba shear zone (41km); 3 - Kilima Mzinga - Kwandege main shear zone (28km); 4 - Mligazi shear zone (15km); and 5 - Magambazi - Mjembe (28km) shear zone. The Company has identified three further key elements in the delineation of gold mineralization which includes the prominence of NE-SW lineaments (seven in total), the role of SW to NE thrust planes and the use of radioelements to outline potential target areas. Three major SW to NE thrusts planes were also identified: a main thrust zone of 46km; and two additional thrusts zones of 5km and 3km each. In addition to the key elements sheath folding, open folds (2km to 10km scale) and boudinage provide additional targets with a second order priority.
The position of regional gold mining activities, as well as known gold mineralization occurrences, were utilized to test the Company’s developed model for locating gold mineralization and this approach proved to be successful. Following from this the Company considers the Kilima Mzinga - Kwandege shear zone, with a distance of 28km in PL6742, PL6779 and PL6744 as one of their primary targets, substantiated by the artisanal mining activities along the northwestern and southwestern outcrop area of the shear. In addition to the shear component along the Kilima Mzinga - Kwandege shear zone, a considerable SW to NE thrust component acted along a 25km long stretch of the shear within the Company’s property adding to the gold mineralization potential of this zone based on the current model.
Harp Sangha, the Company’s CEO, stated: “We are confident that the model developed based on the first exploration phase provides a substantial platform for understanding gold mineralization in the prospecting licenses as exemplified by the success with which the model predicts and outlines existing and known gold anomalies”. Phase two of the exploration program focused on the identified potential zones during an intensive stream sediment and soil sampling program. The results will be released in due course.
The Company has requested a geologist to prepare a Technical Report on the Handeni Project in accordance with the provisions of National Instrument 43-101 (”NI 43-101?) of the Canadian Securities Administrators. Upon receipt of the Technical Report the Company will file it on SEDAR at www.sedar.com.
The technical information in this news release has been prepared in accordance with the Canadian regulatory requirements set out in NI 43-101 and has been reviewed by Reyno Scheepers, Ph.D., Pr.Sci.Nat, Director of Exploration and a director of the Company, a QP under NI 43-101.
Cost Plus Inc. (Nasdaq:CPWM) confirmed that it is conducting a merchandising test with Bed Bath & Beyond involving its consumables products in three Bed Bath & Beyond stores located in San Diego, California; Totowa, New Jersey and Elmsford, New York. Cost Plus continually evaluates merchandising initiatives, including the merchandising test taking place with Bed Bath & Beyond. Cost Plus does not comment on merchandising tests. Cost Plus, Inc. is a leading specialty retailer of casual home living and entertaining products. As of December 10, 2010, the Company operated 263 stores in 30 states.
Cost Plus, Inc., together with its subsidiaries, operates as a specialty retailer of casual home furnishings and entertaining products in the United States. It offers decorating items, including furniture, rugs, pillows, bath linens, lamps, window coverings, frames, and baskets; and furniture products comprising ready-to-assemble living and dining room pieces, handcrafted case goods, occasional pieces, and outdoor furniture made from various materials, such as rattan, hardwood, and wrought iron.
Delcath Systems Inc. (Nasdaq:DCTH) announced that the Company has submitted its CE Mark Technical File to its European Notified Body to obtain CE Mark approval for its proprietary chemosaturation system, which the Company intends to market in the European Union (NYSEARCA:EU) as the Delcath Hepatic ChemoSAT™ Delivery System. CE Marking is an indication that a medical device complies with the essential requirements of applicable medical device directives, and that the device has been subjected to conformity assessment procedures. Receipt of the CE Mark will allow Delcath to market and sell the product in countries in the EU.
Delcath Systems, Inc., a development stage company, develops and manufactures devices to administer high dose chemotherapy and other therapeutic agents directly to diseased organs or regions of the body. It focuses on the development of the Delcath PHP System, a Phase III clinical trial product, which isolates the liver from the patient’s general circulatory system and delivers high dose of melphalan hydrochloride or other therapeutic agents directly to the liver.
Dell Inc. (Nasdaq:DELL) and Goodwill Industries International has added 100 GoodwillÂ® donation sites to the Dell Reconnect computer recycling program, making it convenient for more than 42 million U.S. households to drop off computers and related accessories for free, responsible recycling. The new collection sites, located in Delaware, Massachusetts, Nebraska, Ohio, Pennsylvania, and Rhode Island, are now among more than 2,200 Dell Reconnect collection sites across the United States and Canada. The new sites are expected to divert approximately 5 million pounds of e-waste from landfills each year.
Dell Inc. designs, develops, manufactures, markets, sells, and supports computer systems, as well as provides related services worldwide. It offers desktop PCs; notebook computers, mobile workstations, and smartphones; servers and networking products; storage solutions, including storage area networks, network-attached storage, direct-attached storage, disk and tape backup systems, and removable disk backup; and printers and displays.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).
Sign Up For Free Stock Alerts At http://stock-pr.com/signup
________________________________________Be Sure To Visit stock-pr.ning.com
The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.